Treatment-related neurotoxicity

Area of Science:

• Oncology
• Neurology
• Clinical Therapeutics

Background:

• Primary central nervous system lymphoma (PCNSL) presents significant treatment challenges.
• Current therapies face limitations regarding toxicity and long-term patient outcomes.
• Treatment-related neurotoxicity is a critical complication impacting quality of life.

Purpose of the Study:

• To highlight the dual challenges in PCNSL management: optimizing therapeutic efficacy with reduced toxicity and addressing neurotoxicity.
• To emphasize the need for collaborative research to understand and manage neurotoxicity.
• To advocate for improved reporting standards in clinical trials.

Main Methods:

• Review of current challenges in PCNSL treatment.
• Discussion of the impact of treatment-related neurotoxicity.
• Proposal for enhanced follow-up protocols in therapeutic studies.

Main Results:

• Two primary challenges identified: developing safer, more effective therapies and managing neurotoxicity.
• Neurotoxicity significantly affects long-term outcomes and requires dedicated interventions.
• Current follow-up practices often lack comprehensive assessment of neurocognitive function.

Conclusions:

• Future PCNSL therapeutic strategies must prioritize reduced toxicity and improved long-term survival.
• Enhanced collaborative efforts are essential for understanding and mitigating treatment-related neurotoxicity.
• Prospective studies should incorporate longitudinal neurocognitive assessments to better evaluate treatment effects and complications.